Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- interferon alfa-2b / ribavirin
- Nexium (esomeprazole)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food interactions
ribavirin food
Applies to: interferon alfa-2b / ribavirin
ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.
MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.
References (2)
- (2003) "Product Information. Copegus (ribavirin)." Roche Laboratories
- (2004) "Product Information. Rebetol (ribavirin)." Schering-Plough Corporation
esomeprazole food
Applies to: Nexium (esomeprazole)
ADJUST DOSING INTERVAL: Food may interfere with the absorption of esomeprazole. The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.
MANAGEMENT: Esomeprazole should be taken at least one hour before meals. When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.
References (2)
- (2001) "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Epclusa
Epclusa treats chronic hepatitis C in adults and children 3+. This once-daily antiviral combines ...
Mavyret
Mavyret (glecaprevir/pibrentasvir) is an oral combination medicine containing fixed doses of two ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Harvoni
Harvoni is used to treat hepatitis C virus (HCV) infections in adults and children aged 3 years and ...
Sovaldi
Sovaldi (sofosbuvir) is used to treat chronic hepatitis C virus (HCV) infection. Includes Sovaldi ...
Vosevi
Vosevi (sofosbuvir,velpatasvir and voxilaprevir) is used to treat chronic hepatitis C. Includes ...
Pegasys
Pegasys is used to treat chronic hepatitis B or C. Learn about side effects, interactions and ...
Zepatier
Zepatier (elbasvir and grazoprevir) is used to treat chronic hepatitis C. Includes Zepatier side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.